Dihexa
Purrptide digest
Dihexa was designed in a lab specifically to cross the blood-brain barrier and amplify hepatocyte growth factor activity — a pathway involved in forming new synapses. The headline number researchers cite is that it's roughly 10 million times more potent than BDNF at promoting synapse formation in cell models. That's not a typo, just an extraordinary in-vitro result. Human trial data is essentially nonexistent so far — this remains squarely in animal-model and early-research territory, despite the enthusiasm the potency numbers generate online.
What this means for you
The potency numbers are eye-catching but come from cell studies, not humans. Treat the hype with real skepticism until trials exist.
Zero human clinical data exists. Any patient asking about this should understand they'd be in genuinely uncharted territory.
The HGF/synaptogenesis pathway it targets is real and interesting, but the leap from cell-culture potency to in-vivo effect is the unanswered question.
Designed in a university lab and never advanced to formal clinical trials. The commercial path here is currently nonexistent.
For the nerds
Evaluation of metabolically stabilized angiotensin IV analogs as procognitive agents
Journal of Pharmacology and Experimental Therapeutics · DOI: 10.1124/jpet.112.196733
Read full paper on PubMed →